APG-115
Phase 1Small molecule
Ascentage Pharma Group Inc.APG-115 is one of 147 small molecule programs targeting Salivary Gland Cancer. It is currently in Phase 1.
5
Indications
8
Total Trials
6
Active Trials
146
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Velban
EEastern Cooperative Oncology Group
Preclinical
APG-115
Ascentage Pharma Group Inc.Phase 1
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Phase IB1 trial
Neuroblastoma1 trial
3 more indications
Liposarcoma1 trial
Malignant Salivary Gland Cancer1 trial
A Multicenter Phase I/II Trial of a Novel MDM2 Inhibitor (APG-115) in p53 Wild-type Salivary Gland Carcinoma
Active, not recruiting·UUniversity of Michigan Rogel Cancer Center·Preclinical·NCT03781986·41 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for APG-115. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company